« The epigenome as a therapeutic target | Main | Brookhaven scientists use PET scanning to study kinetics of salvia divinorum »

April 28, 2008

Ipilimumab: Bristol-Myers, Medarex cancer drug delayed

Ipilimumab, the fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), is in clinical trials for the treatment of advanced melanoma, but Reuters is reporting:

Bristol-Myers Squibb Co and Medarex Inc  said Friday they will delay seeking approval of their experimental treatment for advanced melanoma after U.S. health regulators requested additional data on the biotechnology drug.

Because of this, an approval application will not be submitted this year.

TrackBack

TrackBack URL for this entry:
https://www.typepad.com/services/trackback/6a00d8341bffa053ef00e55217fcf48834

Listed below are links to weblogs that reference Ipilimumab: Bristol-Myers, Medarex cancer drug delayed:

Comments

blog comments powered by Disqus